Sugi Predict

Sugi Predict / Targets / STAT5B

STAT5B

Signal transducer and activator of transcription 5B · P51692 · STAT5B on Sugi Atlas →

6,485 patent compounds predicted against STAT5B, 4,216 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL10246347 SCHEMBL10246347 0.54 8/20
SCHEMBL10243281 SCHEMBL10243281 0.73 7/20
SCHEMBL13711680 SCHEMBL13711680 0.51 7/20
SCHEMBL8812940 SCHEMBL8812940 0.44 7/20
SCHEMBL10244955 SCHEMBL10244955 1.00 6/20
SCHEMBL10246024 SCHEMBL10246024 0.91 6/20
SCHEMBL10243331 SCHEMBL10243331 0.88 6/20
SCHEMBL10243794 SCHEMBL10243794 0.88 6/20
SCHEMBL10243467 SCHEMBL10243467 0.87 6/20
SCHEMBL10246169 SCHEMBL10246169 0.87 6/20
SCHEMBL10245224 SCHEMBL10245224 0.87 6/20
SCHEMBL10243181 SCHEMBL10243181 0.86 6/20
SCHEMBL10246070 SCHEMBL10246070 0.86 6/20
SCHEMBL10245129 SCHEMBL10245129 0.84 6/20
SCHEMBL10243782 SCHEMBL10243782 0.83 6/20
SCHEMBL10244407 SCHEMBL10244407 0.77 6/20
SCHEMBL10246029 SCHEMBL10246029 0.76 6/20
SCHEMBL10246148 SCHEMBL10246148 0.66 6/20
SCHEMBL10244946 SCHEMBL10244946 0.62 6/20
SCHEMBL10246173 SCHEMBL10246173 0.61 6/20

Clinical trials — most relevant to STAT5B by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Safety and Efficacy of Tofacitinib in the Treatment of NSAID Refractory Axial Spondyloarthritis:A Clinical Trial PHASE2/PHASE3UNKNOWN
Use of Selective JAK Inhibitor in ILD and Skin Tightness of Systemic Sclerosis Versus MMF PHASE3COMPLETED
Efficacy of Oral Tofacitinib in Moderate to Severe Alopecia Areata, Totalis and Universalis at Tertiary Care Hospital, Karachi. PHASE3COMPLETED
Dual JAK1/TYK2 Inhibitor for Cicatricial Alopecia PHASE2COMPLETED
Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation PHASE1/PHASE2COMPLETED
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients PHASE1RECRUITING
Itacitinib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer PHASE1COMPLETED
Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis PHASE1COMPLETED
Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia PHASE1RECRUITING
Phase 1, Open-label Trial to Determine Safety of OPB-51602 in Subjects With Advanced Cancer PHASE1COMPLETED
Neratinib in Combination With Ruxolitinib in Patients With mTNBC EARLY_PHASE1RECRUITING
Immune Interactions in Severe Asthma nanCOMPLETED
Effect of Different Therapeutic Strategies on Regulatory T Cells in Kidney Transplantation nanCOMPLETED
STAT4 in Multiple Sclerosis by PCR and Flow Cytometry nanCOMPLETED
Gene Expression Of Suppressor Of Cytokines in In Cutaneous Warts nanCOMPLETED
CircularRNA-microRNA-mRNA Regulatory Axis in IVF nanNOT_YET_RECRUITING
Cutaneous JAK in Vitiligo and Acne Vulgaris. nanUNKNOWN
Androgenetic Alopecia and the JAK-STAT Pathway nanCOMPLETED
Impact of Vorinostat on Pruritus Signaling Pathways - Merck Study nanWITHDRAWN
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia nanUNKNOWN
Prohepcidin, Inflammation and Iron Homeostasis in Hemodialysis Patients With Chronic Hepatitis C nanCOMPLETED
Ex Vivo Evaluation of JAK-inhibitor and Gene Therapeutical Approach in JAK-STAT Related Disorders nanRECRUITING
Study of Proteins in Promoting Chemotherapy Resistance in Samples From Patients With Acute Myeloid Leukemia nanCOMPLETED
Studying Biomarkers in Cell Samples From Young Patients With Acute Myeloid Leukemia nanCOMPLETED
Recombinant Interferon Alfa-2b in Treating Patients With Melanoma nanCOMPLETED
Prognostic Biomarkers in Samples From Young Patients With Acute Myeloid Leukemia nanCOMPLETED
Prospective Observational Study Evaluating the Safety and Efficacy of Immunomodulatory Therapies in Refractory Inflammatory and Autoimmune Diseases nanNOT_YET_RECRUITING
Use of Mucomyst to Ameliorate Oxidant Stress in Diabetics With Proteinuria nanCOMPLETED
Lestaurtinib With or Without Chemotherapy Agents in Samples From Young Patients With Leukemia nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a STAT5B binder may also engage these)

ProteinNameSimilarity
Q9TUM3 — 1.000 Q9TUM3 →
Q9TUZ0 — 1.000 Q9TUZ0 →
P42232 — 1.000 P42232 →
P52632 — 1.000 P52632 →
Q95115 — 1.000 Q95115 →
Q9TUZ1 — 1.000 Q9TUZ1 →
STAT5A Signal transducer and activator of transcription 5A 1.000 landscape →
Q62771 — 1.000 Q62771 →
P42230 — 1.000 P42230 →
P42231 — 0.992 P42231 →
P42227 — 0.968 P42227 →
P52631 — 0.968 P52631 →
Q9ERA0 — 0.967 Q9ERA0 →
P61635 — 0.966 P61635 →
Q12800 — 0.965 Q12800 →
Q6NZH6 — 0.965 Q6NZH6 →
Q6DV79 — 0.965 Q6DV79 →
Q6ZUT9 — 0.965 Q6ZUT9 →
Q9PVX8 — 0.964 Q9PVX8 →
STAT1 Signal transducer and activator of transcription 1-alpha/beta 0.963 landscape →
Q4V860 — 0.962 Q4V860 →
Q7Z6J6 — 0.962 Q7Z6J6 →
Q8R3S6 — 0.962 Q8R3S6 →
Q7T2U9 — 0.962 Q7T2U9 →
Q8K4Q0 — 0.962 Q8K4Q0 →
RPTOR Regulatory-associated protein of mTOR 0.961 landscape →
Q9Y3P9 — 0.961 Q9Y3P9 →
Q5RAN1 — 0.960 Q5RAN1 →
Q8IZD9 — 0.960 Q8IZD9 →
EXOC1 Exocyst complex component 1 0.960 landscape →